180 Life Sciences (ATNFW) Stock Price, News & Analysis

Company Overview

180 Life Sciences (NASDAQ: ATNFW) is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and pain. The company’s scientific approach centers on targeting ion channels and inflammatory pathways to create therapies that address underlying disease mechanisms rather than merely managing symptoms. By leveraging proprietary chemistry and translational research, 180 Life Sciences aims to advance its drug candidates from preclinical studies into human trials.

The company’s pipeline includes a lead pain management program designed to modulate the transient receptor potential vanilloid 1 (TRPV1) channel, which plays a key role in the transmission of pain signals. In parallel, 180 Life Sciences is progressing an oncology asset intended to disrupt tumor-supporting microenvironments, with the goal of enhancing the efficacy of existing cancer treatments. Each program has shown promising preclinical data, and the company is preparing to initiate clinical studies in select patient populations.

Operating primarily in North America and Europe, 180 Life Sciences maintains research collaborations with academic institutions and contract research organizations to support its discovery and development activities. Headquartered in New York City, the company integrates medicinal chemistry, pharmacology, and translational science to accelerate its drug development timelines. Through strategic partnerships and a focused pipeline, 180 Life Sciences is positioned to bring differentiated therapies to market in areas of high unmet medical need.

Key Stats

• Today's Range: $0.03 to $0.05
• 50-Day Range: $0.03 to $0.08
• 52-Week Range: $0.00 to $0.62
• Volume: 1.22 million shs
• Average Volume: 501,334 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATNFW
• CIK: 1690080
• Web: 180lifesciences.com
• Phone: 650-507-0669
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A